IBD treatment is linked to cancer

Treatment for inflammatory bowel disease may increase patients' risk of infection-related cancer, research published in The Lancet suggests.

IBD treatment was researched
IBD treatment was researched

Laurent Beaugerie and colleagues from the St Antoine Hospital in Paris studied data from 19,486 patients who had Crohn's disease or ulcerative colitis.

The patients were assessed over an average of 35 months.

The researchers found that patients' risk of developing lymphoproliferative disorders was over five times higher for those treated with thiopurines, compared with those who had never received the drugs.

Old age, male sex and longer duration of inflammatory bowel disease were also associated with an increased risk of incident lymphoproliferative disorder.

However, the absolute risk remains low, the researchers pointed out, at around 90 cases per 100,000 patients.

The researchers believe that the excess risk may be due to the inflammatory process itself, or to thiopurine exposure, or to a combination of the two.

However, they said that it was not clear whether the risk of incident lymphoproliferative disorder was also increased in patients receiving other immunosuppressants.

In addition, they do not suggest that use of thiopurines should be reconsidered.

'Extrapolating our results, the absolute cumulative risk of lymphoproliferative disorder in young patients receiving a 10-year course of thiopurines remains low (<1%) and does not undermine the positive risk-benefit ratio of these drugs,' they said.

'For elderly patients and unlimited treatment periods, the question should be addressed in dedicated studies,' they added.

GP Online recommends

Lancet Online 2009

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK have led the largest-ever NHS vaccination programme in response...

RCGP chair Professor Martin Marshall

Hand PCNs control of primary care infrastructure funding, says RCGP

CCG funding for primary care infrastructure should be handed to PCNs when the bodies...

Professor Martin Marshall and Talking General Practice logo

Podcast: RCGP chair Professor Martin Marshall

Talking General Practice speaks to RCGP chair Professor Martin Marshall.

Dr Chaand Nagpaul

In-house review not enough to stop 'unjust' GMC referrals, warns BMA

Doctors' leaders have repeated calls for a full independent review of the GMC referral...


How widespread is long COVID in the UK?

Millions of people in the UK are living with long COVID. GPonline looks at the data...

COVID-19 vaccination sign

GP contract for autumn COVID-19 booster campaign due shortly

GP practices in England will be invited shortly to sign up for the COVID-19 autumn...